TY - JOUR
T1 - Serum levels of macrophage colony-stimulating factor in trophoblastic disease
AU - Kohorn, Ernest I.
AU - Kacinski, Barry M.
AU - Stanley, E. Richard
N1 - Funding Information:
1Supported by the Baumer Fund of Yale University and National Institute of Health Grants CA26504 and CA32551 (to E.R.S.) and the Albert Einstein Cancer Center Grant P30-13330.
PY - 2001
Y1 - 2001
N2 - Objectives. The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole. Methods. Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor, hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule. CSF-1 was measured by radioimmunoassay with 125I-labeled recombinant CSF-1. The upper level of normal CSF-1 was taken as 8 ng/ml. Results. In this study of 45 patients with trophoblastic disease, some very high levels of CSF-1 were encountered. In a few patients there was dramatic correlation with hCG. Generally, however, CSF-1 and hCG did not correlate. CSF-1 was frequently not elevated when hCG was still significantly elevated and conversely CSF-1 was elevated when hCG was negative. Conclusion: The measurement of CSF-1 does not appear to be useful in managing trophoblastic disease as it does not correlate with the level of hCG. Occasionally, high levels of CSF-1 were found in patients with trophoblastic disease.
AB - Objectives. The aims of this study were to measure levels of colony stimulating factor (CSF-1) in patients with trophoblastic disease, to determine whether such measurement may be useful to supplement measurement of the prognostically reliable human chorionic gonadotrophin (hCG), and to assess whether measurement of CSF-1 may be helpful in predicting requirement for chemotherapy in patients with hydatidiform mole. Methods. Serial weekly serum samples were selected for CSF-1 assay from representative diagnostic groups of patients with trophoblastic disease: hydatidiform-mole with spontaneous resolution, low-risk post-hydatidiform-mole trophoblastic tumor, partial hydatidiform mole, high-risk metastatic gestational trophoblastic tumor, primary ovarian choriocarcinoma, and placental site trophoblastic tumor, hCG was measured by an in-house radioimmunoassay that measures all parts of the hCG molecule. CSF-1 was measured by radioimmunoassay with 125I-labeled recombinant CSF-1. The upper level of normal CSF-1 was taken as 8 ng/ml. Results. In this study of 45 patients with trophoblastic disease, some very high levels of CSF-1 were encountered. In a few patients there was dramatic correlation with hCG. Generally, however, CSF-1 and hCG did not correlate. CSF-1 was frequently not elevated when hCG was still significantly elevated and conversely CSF-1 was elevated when hCG was negative. Conclusion: The measurement of CSF-1 does not appear to be useful in managing trophoblastic disease as it does not correlate with the level of hCG. Occasionally, high levels of CSF-1 were found in patients with trophoblastic disease.
UR - http://www.scopus.com/inward/record.url?scp=0035093331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035093331&partnerID=8YFLogxK
U2 - 10.1006/gyno.2000.6090
DO - 10.1006/gyno.2000.6090
M3 - Article
C2 - 11263936
AN - SCOPUS:0035093331
SN - 0090-8258
VL - 80
SP - 383
EP - 386
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -